Track Coherus BioSciences, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Coherus BioSciences, Inc. CHRS · Stock Open Coherus BioSciences, Inc. in new tab

0.5249 USD
P/E
3.04
EPS
-1.12
P/B
3.22
ROE
-275.17
Beta
1.05
Target Price
7.25 USD
Coherus BioSciences, Inc. logo

Coherus BioSciences, Inc.

🧾 Earnings Recap – Q3 2026

Coherus shares fell 21.6% after earnings, as investors appear to have focused on the company’s need to sharply reduce costs and its reliance on growing LOQTORZI revenue to cover core cash burn. Management plans a 30% headcount reduction and narrowed tagmokitug development to esophageal cancer, but the transcript does not provide evidence that LOQTORZI has yet reached the revenue level needed to support the business.

  • Coherus expects rightsizing and other cost reductions to save $6 million–$7 million per quarter, lowering the LOQTORZI revenue needed to cover core cash burn from $30 million–$35 million to $25 million–$30 million per quarter.
  • The company plans to cut headcount by 30% and focus tagmokitug development on first- and second-line esophageal cancer, after exploring multiple cancer types and more than 120 patients.
  • Management cited interim tagmokitug data in combination with toripalimab as support for seeking ex-U.S. partners; it is engaging a financial adviser to conduct the partnering process.
  • LOQTORZI’s share of the nasopharyngeal cancer market is about 20%–22%, while roughly 30% of patients still receive chemotherapy alone, which management sees as a growth opportunity.
  • Management said the U.S. manufacturing process transfer for toripalimab was completed in Q3 2026; the FDA action date for the drug-product portion of the application is November 30.
📅
Loading chart...
Key Metrics
Earnings dateMarch 8, 2027
P/E3.04
EPS-1.12
Book Value0.16
Price to Book3.22
Debt/Equity275.45
% Insiders19.703%
Growth
Revenue Growth0.23%
Estimates
Forward P/E-0.83
Forward EPS-0.63
Target Mean Price7.25

DCF valuation

Model fair value for Coherus BioSciences, Inc. (CHRS)
Result
Sign in to run the valuation for CHRS.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
4 analysts · consensus Strong buy · mean target 7.25 USD (low 4.00, high 10.00) · as of 15 Nov 2026
Low 4.00
Mean 7.25
High 10.00
Price 0.5249
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Coherus BioSciences, Inc. Logo Coherus BioSciences, Inc. Analysis (CHRS)

United States Health Care Official Website Stock

Is Coherus BioSciences, Inc. a good investment? Coherus BioSciences, Inc. (CHRS) is currently trading at 0.5249 USD. Market analysts have a consensus price target of 7.25 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 3.04. This relatively low multiple may signal that Coherus BioSciences, Inc. is undervalued compared to historical market norms.

Earnings Schedule: Coherus BioSciences, Inc. is expected to release its next earnings report on March 8, 2027. The market consensus estimate for Forward EPS is -0.63.

Investor FAQ

Does Coherus BioSciences, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Coherus BioSciences, Inc.?

Coherus BioSciences, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 8, 2027. The company currently has a trailing EPS of -1.12.

Company Profile

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.

Exchange Ticker
NMS (United States) CHRS
FRA (Germany) 8C5.F
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion